Terms: = Leukemia AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR
2262 results:
1. Trends in childhood leukemia incidence in urban countries and their relation to environmental factors, including space weather.
Khabarova O; Pinaev SK; Chakov VV; Chizhov AY; Pinaeva OG
Front Public Health; 2024; 12():1295643. PubMed ID: 38756895
[TBL] [Abstract] [Full Text] [Related]
2. Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation.
Jiang Y; Feng D; Zhu J; Wei D; Zhao C; Liu H; Shao S; Wang C
Front Immunol; 2024; 15():1381308. PubMed ID: 38745670
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of the efficacy and safety of car T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis.
Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR
Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799
[TBL] [Abstract] [Full Text] [Related]
4. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic leukemia.
Verbeek MWC; van der Velden VHJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
[TBL] [Abstract] [Full Text] [Related]
5. Stealth transgenes enable car-T cells to evade host immune responses.
Grauwet K; Berger T; Kann MC; Silva H; Larson R; Leick MB; Bailey SR; Bouffard AA; Millar D; Gallagher K; Turtle CJ; Frigault MJ; Maus MV
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724463
[TBL] [Abstract] [Full Text] [Related]
6. Recent advances in car-T cell therapy for acute myeloid leukaemia.
Gao C; Li X; Xu Y; Zhang T; Zhu H; Yao D
J Cell Mol Med; 2024 May; 28(9):e18369. PubMed ID: 38712978
[TBL] [Abstract] [Full Text] [Related]
7. Off-the-shelf car-T cell therapies for relapsed or refractory B-cell malignancies: latest update from ASH 2023 annual meeting.
Kang Y; Li C; Mei H
J Hematol Oncol; 2024 May; 17(1):29. PubMed ID: 38711046
[TBL] [Abstract] [Full Text] [Related]
8. Breast Relapse of Pediatric B-Cell Acute Lymphoblastic leukemia After car-T Therapy Detected by
Perrone E; Taralli S; Pagliara D; Larocca LM; Vinti L; Leccisotti L
Anticancer Res; 2024 May; 44(5):2243-2245. PubMed ID: 38677722
[TBL] [Abstract] [Full Text] [Related]
9. Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 car T Lymphocytes.
Khvorost D; Kendall B; Jazirehi AR
Cells; 2024 Apr; 13(8):. PubMed ID: 38667277
[TBL] [Abstract] [Full Text] [Related]
10. Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center.
Hao Z; Fei Y; Chen J; Huang S; Wang L; Yu Y; Bian M; Si Y; Zhang X; Yang X; Zhang B; Wan Y; Zhang Y; Lin G
Hematology; 2024 Dec; 29(1):2344998. PubMed ID: 38666535
[TBL] [Abstract] [Full Text] [Related]
11. Infectious complications in pediatric patients undergoing CD19+CD22+ chimeric antigen receptor T-cell therapy for relapsed/refractory B-lymphoblastic leukemia.
Wu X; Cao Z; Chen Z; Wang Y; He H; Xiao P; Hu S; Lu J; Li B
Clin Exp Med; 2024 Apr; 24(1):87. PubMed ID: 38662121
[TBL] [Abstract] [Full Text] [Related]
12. Overcoming the challenges encountered in car-T therapy: latest updates from the 2023 ASH annual conference.
Zhang T; Zhang Y; Wei J
Front Immunol; 2024; 15():1389324. PubMed ID: 38660304
[TBL] [Abstract] [Full Text] [Related]
13. Sequential CD7 car T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H
N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244
[TBL] [Abstract] [Full Text] [Related]
14. Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.
Chen LY; Kothari J
Curr Opin Support Palliat Care; 2024 Jun; 18(2):92-99. PubMed ID: 38652455
[TBL] [Abstract] [Full Text] [Related]
15. Conventional and novel [
Leithner D; Flynn JR; Devlin SM; Mauguen A; Fei T; Zeng S; Zheng J; Imber BS; Hubbeling H; Mayerhoefer ME; Bedmutha A; Luttwak E; Corona M; Dahi PB; Luna de Abia A; Landego I; Lin RJ; Palomba ML; Scordo M; Park JH; Tomas AA; Salles G; Lafontaine D; Michaud L; Shah GL; Perales MA; Shouval R; Schöder H
J Hematol Oncol; 2024 Apr; 17(1):21. PubMed ID: 38649972
[TBL] [Abstract] [Full Text] [Related]
16. Implantable car T cell factories enhance solid tumor treatment.
Pandit S; Agarwalla P; Song F; Jansson A; Dotti G; Brudno Y
Biomaterials; 2024 Jul; 308():122580. PubMed ID: 38640784
[TBL] [Abstract] [Full Text] [Related]
17. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
Dabkowska A; Domka K; Firczuk M
Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
[TBL] [Abstract] [Full Text] [Related]
18. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.
Ma S; Wang Y; Qi K; Lu W; Qi Y; Cao J; Niu M; Li D; Sang W; Yan Z; Zhu F; Cheng H; Li Z; Zhao M; Xu K
Cancer Immunol Immunother; 2024 Apr; 73(6):104. PubMed ID: 38630258
[TBL] [Abstract] [Full Text] [Related]
19. Intention-to-treat outcomes utilising a stringent event definition in children and young people treated with tisagenlecleucel for r/r ALL through a national access scheme.
Oporto Espuelas M; Burridge S; Kirkwood AA; Bonney D; Watts K; Shenton G; Jalowiec KA; O'Reilly MA; Roddie C; Castleton A; Clesham K; Nicholson E; Alajangi R; Prabhu S; George L; Uttenthal B; Gabelli M; Neill L; Besley C; Chaganti S; Wynn RF; Bartram J; Chiesa R; Lucchini G; Pavasovic V; Rao A; Rao K; Silva J; Samarasinghe S; Vora A; Clark P; Cummins M; Marks DI; Amrolia P; Hough R; Ghorashian S
Blood Cancer J; 2024 Apr; 14(1):66. PubMed ID: 38622139
[TBL] [Abstract] [Full Text] [Related]
20. Oncotherapy resistance explained by Darwinian and Lamarckian models.
Saunthararajah Y
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618954
[TBL] [Abstract] [Full Text] [Related]
[Next]